Cue Historical Financial Ratios

CUE Stock

USD 1.17 0.05 4.10%

Cue Biopharma is presently reporting on over 100 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 3.09 or Days Sales Outstanding of 99.03 will help investors to properly organize and evaluate Cue Biopharma financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

About Cue Financial Ratios Analysis

Cue BiopharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cue Biopharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cue financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cue Biopharma history.

Cue Biopharma Financial Ratios Chart

At present, Cue Biopharma's Cash Per Share is projected to increase slightly based on the last few years of reporting. The current year's Tangible Book Value Per Share is expected to grow to 1.40, whereas PTB Ratio is forecasted to decline to 3.09.

Price To Sales Ratio Ptb Ratio Days Sales Outstanding Book Value Per Share Revenue Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Cue Biopharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cue Biopharma sales, a figure that is much harder to manipulate than other Cue Biopharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most ratios from Cue Biopharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.At present, Cue Biopharma's Cash Per Share is projected to increase slightly based on the last few years of reporting. The current year's Tangible Book Value Per Share is expected to grow to 1.40, whereas PTB Ratio is forecasted to decline to 3.09.

	2021	2022	2023	2024 (projected)
Days Sales Outstanding	76.77	16.78	112.89	99.03
PTB Ratio	5.4	1.55	3.26	3.09

Days Sales Outstanding Ptb Ratio

Cue Biopharma fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.3	0.02	0.09	0.49	0.19	-0.51	0.31	0.3	0.99	0.18	0.57	-0.71	0.13	0.56	0.22	0.82	0.4	0.09	-0.31	-0.75	-0.3	-0.32	0.46	0.1	0.63
Ptb Ratio	0.3		-0.12	-0.82	0.73	0.91	-0.67	0.98	1.0	0.28	0.9	0.57	-0.16	0.93	0.63	-0.49	0.56	0.71	-0.85	-0.99	-0.37	-0.98	-1.0	0.78	0.63	0.75
Days Sales Outstanding	0.02	-0.12		0.18	0.16	-0.09	-0.16	-0.14	-0.12	0.09	-0.09	-0.44	0.28	-0.12	-0.23	0.38	0.17	-0.18	0.18	0.13	0.3	0.15	0.13	-0.29	-0.2	-0.15
Book Value Per Share	0.09	-0.82	0.18		-0.32	-0.8	0.4	-0.78	-0.82	0.14	-0.8	-0.22	-0.26	-0.85	-0.38	0.51	-0.18	-0.56	1.0	0.79	-0.07	0.78	0.79	-0.58	-0.6	-0.3
Free Cash Flow Yield	0.49	0.73	0.16	-0.32		0.68	-0.71	0.67	0.73	0.53	0.67	0.55	-0.42	0.68	0.68	-0.25	0.76	0.61	-0.39	-0.72	-0.6	-0.69	-0.74	0.6	0.41	0.89
Operating Cash Flow Per Share	0.19	0.91	-0.09	-0.8	0.68		-0.73	0.89	0.91	0.14	1.0	0.53	0.05	0.98	0.59	-0.66	0.49	0.79	-0.83	-0.9	-0.2	-0.89	-0.91	0.89	0.36	0.69
Average Payables	-0.51	-0.67	-0.16	0.4	-0.71	-0.73		-0.67	-0.67	-0.51	-0.71	-0.26	0.15	-0.65	-0.8	0.17	-0.83	-0.79	0.44	0.66	0.31	0.67	0.68	-0.74	0.04	-0.59
Capex To Depreciation	0.31	0.98	-0.14	-0.78	0.67	0.89	-0.67		0.98	0.28	0.88	0.56	-0.15	0.89	0.64	-0.5	0.56	0.75	-0.81	-0.99	-0.36	-1.0	-0.99	0.8	0.53	0.72
Pb Ratio	0.3	1.0	-0.12	-0.82	0.73	0.91	-0.67	0.98		0.28	0.9	0.57	-0.16	0.93	0.63	-0.49	0.56	0.71	-0.85	-0.99	-0.37	-0.98	-1.0	0.78	0.63	0.75
Ev To Sales	0.99	0.28	0.09	0.14	0.53	0.14	-0.51	0.28	0.28		0.13	0.5	-0.7	0.09	0.57	0.32	0.84	0.35	0.13	-0.28	-0.74	-0.27	-0.3	0.39	0.11	0.61
Free Cash Flow Per Share	0.18	0.9	-0.09	-0.8	0.67	1.0	-0.71	0.88	0.9	0.13		0.53	0.07	0.99	0.57	-0.66	0.47	0.76	-0.83	-0.9	-0.18	-0.89	-0.91	0.89	0.37	0.68
Roic	0.57	0.57	-0.44	-0.22	0.55	0.53	-0.26	0.56	0.57	0.5	0.53		-0.59	0.54	0.35	-0.48	0.37	0.38	-0.26	-0.59	-0.71	-0.57	-0.6	0.68	0.44	0.86
Inventory Turnover	-0.71	-0.16	0.28	-0.26	-0.42	0.05	0.15	-0.15	-0.16	-0.7	0.07	-0.59		0.06	-0.38	0.0	-0.51	-0.25	-0.22	0.16	0.96	0.17	0.17	-0.15	-0.23	-0.61
Net Income Per Share	0.13	0.93	-0.12	-0.85	0.68	0.98	-0.65	0.89	0.93	0.09	0.99	0.54	0.06		0.53	-0.64	0.41	0.69	-0.88	-0.92	-0.18	-0.89	-0.93	0.83	0.5	0.67
Days Of Inventory On Hand	0.56	0.63	-0.23	-0.38	0.68	0.59	-0.8	0.64	0.63	0.57	0.57	0.35	-0.38	0.53		-0.09	0.85	0.84	-0.41	-0.63	-0.55	-0.64	-0.64	0.7	0.18	0.63
Payables Turnover	0.22	-0.49	0.38	0.51	-0.25	-0.66	0.17	-0.5	-0.49	0.32	-0.66	-0.48	0.0	-0.64	-0.09		0.07	-0.51	0.55	0.5	0.15	0.52	0.51	-0.57	-0.14	-0.41
Average Inventory	0.82	0.56	0.17	-0.18	0.76	0.49	-0.83	0.56	0.56	0.84	0.47	0.37	-0.51	0.41	0.85	0.07		0.73	-0.21	-0.55	-0.65	-0.56	-0.57	0.6	0.11	0.7
Capex To Revenue	0.4	0.71	-0.18	-0.56	0.61	0.79	-0.79	0.75	0.71	0.35	0.76	0.38	-0.25	0.69	0.84	-0.51	0.73		-0.59	-0.72	-0.46	-0.76	-0.73	0.82	0.08	0.62
Cash Per Share	0.09	-0.85	0.18	1.0	-0.39	-0.83	0.44	-0.81	-0.85	0.13	-0.83	-0.26	-0.22	-0.88	-0.41	0.55	-0.21	-0.59		0.82	-0.02	0.81	0.82	-0.6	-0.6	-0.36
Pocfratio	-0.31	-0.99	0.13	0.79	-0.72	-0.9	0.66	-0.99	-0.99	-0.28	-0.9	-0.59	0.16	-0.92	-0.63	0.5	-0.55	-0.72	0.82		0.37	0.99	1.0	-0.79	-0.59	-0.75
Interest Coverage	-0.75	-0.37	0.3	-0.07	-0.6	-0.2	0.31	-0.36	-0.37	-0.74	-0.18	-0.71	0.96	-0.18	-0.55	0.15	-0.65	-0.46	-0.02	0.37		0.37	0.38	-0.38	-0.32	-0.78
Capex To Operating Cash Flow	-0.3	-0.98	0.15	0.78	-0.69	-0.89	0.67	-1.0	-0.98	-0.27	-0.89	-0.57	0.17	-0.89	-0.64	0.52	-0.56	-0.76	0.81	0.99	0.37		0.99	-0.8	-0.53	-0.74
Pfcf Ratio	-0.32	-1.0	0.13	0.79	-0.74	-0.91	0.68	-0.99	-1.0	-0.3	-0.91	-0.6	0.17	-0.93	-0.64	0.51	-0.57	-0.73	0.82	1.0	0.38	0.99		-0.81	-0.58	-0.77
Days Payables Outstanding	0.46	0.78	-0.29	-0.58	0.6	0.89	-0.74	0.8	0.78	0.39	0.89	0.68	-0.15	0.83	0.7	-0.57	0.6	0.82	-0.6	-0.79	-0.38	-0.8	-0.81		0.16	0.74
Income Quality	0.1	0.63	-0.2	-0.6	0.41	0.36	0.04	0.53	0.63	0.11	0.37	0.44	-0.23	0.5	0.18	-0.14	0.11	0.08	-0.6	-0.59	-0.32	-0.53	-0.58	0.16		0.45
Roe	0.63	0.75	-0.15	-0.3	0.89	0.69	-0.59	0.72	0.75	0.61	0.68	0.86	-0.61	0.67	0.63	-0.41	0.7	0.62	-0.36	-0.75	-0.78	-0.74	-0.77	0.74	0.45

Click cells to compare fundamentals

Cue Biopharma Account Relationship Matchups

Cue Biopharma fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	101.19	113.78	23.68	81.59	22.0	20.9
Ptb Ratio	6.41	4.55	5.4	1.55	3.26	3.09
Book Value Per Share	2.48	2.75	2.09	1.84	0.81	1.4
Free Cash Flow Yield	(0.0881)	(0.0922)	(0.11)	(0.41)	(0.33)	(0.35)
Operating Cash Flow Per Share	(1.4)	(1.13)	(1.24)	(1.17)	(0.87)	(0.92)
Stock Based Compensation To Revenue	1.89	3.32	0.77	7.63	1.49	1.42
Capex To Depreciation	0.008973	0.56	(0.51)	0.0945	0.11	0.1
Pb Ratio	6.41	4.55	5.4	1.55	3.26	3.09
Ev To Sales	90.06	92.31	20.05	55.65	15.84	15.05
Roic	(1.16)	(0.63)	(0.54)	(0.003754)	(1.15)	(1.21)
Net Income Per Share	(1.66)	(1.56)	(1.41)	(1.48)	(1.11)	(1.16)
Payables Turnover	31.14	16.2	(0.69)	0.66	10.88	6.51
Sales General And Administrative To Revenue	3.68	4.64	1.16	12.98	3.04	2.89
Research And Ddevelopement To Revenue	7.95	10.63	2.77	30.98	7.43	7.06
Capex To Revenue	0.0134	0.19	0.0611	0.14	0.16	0.15
Cash Per Share	2.7	2.96	2.06	2.14	1.06	1.51
Pocfratio	(11.36)	(11.04)	(9.11)	(2.43)	(3.02)	(3.17)
Capex To Operating Cash Flow	(0.001505)	(0.0183)	(0.0235)	(0.004084)	(0.003676)	(0.00386)
Pfcf Ratio	(11.34)	(10.85)	(8.9)	(2.42)	(3.02)	(3.17)
Days Payables Outstanding	11.72	22.53	(531.84)	551.93	33.54	31.87
Income Quality	0.68	0.84	0.73	0.88	0.79	0.61
Roe	(1.15)	(0.67)	(0.57)	(0.8)	(1.37)	(1.44)
Ev To Operating Cash Flow	(10.11)	(8.96)	(7.71)	(1.66)	(2.18)	(2.29)
Pe Ratio	(2.43)	(9.53)	(8.01)	(1.92)	(2.38)	(2.5)
Return On Tangible Assets	(0.51)	(0.45)	(0.53)	(0.58)	(0.82)	(0.87)
Ev To Free Cash Flow	(10.1)	(8.8)	(7.54)	(1.65)	(2.18)	(2.29)
Earnings Yield	(0.41)	(0.1)	(0.12)	(0.52)	(0.42)	(0.44)
Net Debt To E B I T D A	1.07	1.54	1.2	0.64	0.73	0.7
Current Ratio	5.24	5.36	5.35	6.68	3.01	2.86
Tangible Book Value Per Share	2.48	2.75	2.09	1.84	0.81	1.4
Graham Number	9.63	9.83	8.15	7.84	4.5	5.38
Shareholders Equity Per Share	2.48	2.75	2.09	1.84	0.81	1.4
Capex Per Share	0.002103	0.0207	0.0292	0.00479	0.005508	0.005233
Graham Net Net	2.29	2.28	1.56	1.42	0.55	0.53

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:

How To Invest In Cue

Details

Is Cue Stock a good investment?

Details

What is Cue Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.91)

Revenue Per Share

0.172

Quarterly Revenue Growth

0.923

Return On Assets

(0.52)

Return On Equity

(1.39)

The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Cue Historical Financial Ratios

About Cue Financial Ratios Analysis

Cue Biopharma Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Book Value Per Share

Revenue Per Share

Cue Biopharma fundamentals Correlations

Cue Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cue Biopharma fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Cash Per Share	+ 1.0	Book Value Per Share
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Sales	+ 0.99	Price To Sales Ratio
Net Income Per Share	+ 0.99	Free Cash Flow Per Share

Pfcf Ratio	- 1.0	Pb Ratio
Capex To Operating Cash Flow	- 1.0	Capex To Depreciation
Pfcf Ratio	- 1.0	Ptb Ratio
Pocfratio	- 0.99	Pb Ratio
Pfcf Ratio	- 0.99	Capex To Depreciation
Pocfratio	- 0.99	Capex To Depreciation